Financings In Brief
This article was originally published in The Gray Sheet
Executive Summary
ReGen Biologics raises funds for Menaflex launch: U.S. launch of collagen knee cartilage repair implant in February will be supported in part by proceeds from a $10 million private placement of common stock, announced Jan. 21. The Hackensack, N.J., firm completed the first $7 million in funding on Jan. 16 and will raise $3 million more in a planned second stage, ReGen explains. The financing round was led by Sanderling Venture Partners. Menaflex gained 510(k) clearance in December (1"The Gray Sheet" Jan. 5, 2009, p. 24)